

Does the innovative research for allergy and respiratory disease in the European Union benefit patients and what's new?

Co-Hosted by MEPs Catherine STIHLER & Petru LUHAN

European Parliament, Room A3G-2

Tuesday, 17 June 2014 12.30 – 16.00

Event Programme

12.30	Lunch reception prior to the event in front of the meeting room
Session 1: Updates on innovative research for allergy and respiratory disease in the EU	
13.00	Introduction – Members of European Parliament, TBC
13.10	EFA's experience in EU research projects – Breda Flood (EFA President)
13.20	An overview of the EC's research initiatives for healthcare - Karim Berkouk (European Commission, DG RESEARCH)
13.30	Airways Disease Predicting Outcomes through Patient Specific Computational Modelling (AIRPROM) – Chris Brightling (University of Leicester - Project Coordinator), Gay Bottemley (Patient)
13.45	Mechanisms of the Development of Allergy (MeDALL) – Charles Auffrey (Université de Lyon, European Institute for Systems Biology and Medicine, Per-Ake Wecksell (EFA Board Secretary)
14.00	Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) – Louise Fleming (Imperial College – Pediatric Lead), David Supple (Patient Input Platform Chair)
14.15	European Asthma and Innovation Partnership (EARIP) – Samantha Walker (Asthma UK – Project Coordinator)
Session 2: Panel Discussions concerning the impact of patients on EU research	
14.30	Panel Session 1: How will the projects shape a better future for patients and healthcare systems with the burden of respiratory diseases? Charles Auffrey, Université de Lyon, European Institute for Systems Biology and Medicine Michael Hübel, European Commission, DG Health and Consumers, Head of Unit Leonardo Palumbo, Policy Coordinator for EU Affairs and Governance, European Public Health Alliance (EPHA) Professor Mike Thomas, University of Southampton, IPCRG Chair of Research Moderator: David Supple, U-BIOPRED Patient Input Platform Chair
14.55	Discussion: Q&A
15.10	Panel Session 2: How could a European Patient Input Platform (EPIP) benefit EU projects? Louise Fleming (U-BIOPRED - Imperial College, UK) Anders Olauson (European Patients Forum, President) Karim Berkouk, European Commission, DG RESEARCH Catherine Stihler, Member of European Parliament David Supple, U-BIOPRED PIP Chair Moderator: Scott Wagers, BioSci Consulting
15.30	Discussion: Q&A
15.45	Closing Remarks from Catherine Stihler, MEP

Does the innovative research for allergy and respiratory disease in the European Union benefit patients and what's new?

Purpose:

EFA's event at the European Parliament will present four ongoing EU funded research projects where patients are actively participating and should stand to benefit from their outputs. The project coordinators from each of these EU projects will have an opportunity to explain how patients have played a meaningful role. Panel discussions will inquire into describing ways in which European patients, research initiatives and the EU as a whole all stand to benefit from such projects. These benefits will be assessed from the perspectives of the project coordinators, patient representatives and policymakers.

Aims:

The programme above outlines one example of an approach which can aim towards:

1. Educating the public and policymakers on a diverse range of the different EU projects focused on respiratory diseases along with their goals and anticipated outcomes (or actual results if there are any at that time)
2. Demonstrate the utility of EU-funded research projects for patients and how integrating patients into the projects is beneficial
3. Informing relevant stakeholders in attendance of ways project outcomes could assist European healthcare systems and improve patients' quality of life in the future

Outcomes:

1. Establish a precedent for future events for each of the EU projects involved
2. Attraction of interest from diverse groups of stakeholders and increase awareness of the projects among policymakers at the European institutions
3. Clear demonstration of how patient involvement in research is beneficial and how EU funded projects serve the interests of patients and healthcare systems



AIRPROM (Airways Disease Predicting Outcomes through Patient Specific Computational Modelling) – to bridge the gaps in the clinical management of airways disease, by customising a lung model for patients to accurately predict their reaction to medications, in order to permit personalised treatments. <http://www.airprom.eu>

EARIP (European Asthma Research & Innovation Partnership) – to promote best practices for Europe through national asthma programmes, by identifying research gaps and establishing strong stakeholder networks for research and change within healthcare systems. <http://www.earip.eu>

MeDALL (Mechanisms of the Development of Allergy) – to improve the health of European citizens by generating knowledge on the mechanisms of initiation of allergy, in order to propose early diagnosis, prevention and targets for therapy. <http://medall-fp7.eu/>

U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) – to create a handprint (characteristics) for the different ways severe asthma affects patients that will serve to develop new medicines more easily. <http://www.ubiopred.eu>

This programme arises from the EFA 2014 Operating Grant, which has received funding from the European Union, in the framework of the Health Programme (2008-2013).

Disclaimer: The content of this programme is EFA's sole responsibility; it can in no way be taken to reflect the views of the European Commission and/or the Consumers, Health and Food Executive Agency (CHAFAEA) or any other body of the European Union. The European Commission and/or the Executive Agency do(es) not accept responsibility for any use that may be made of the information it contains.

